Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30479180 | 0.98 | MAPT (0.46) | MAPTCYP1A2RECQLKDM4EMMP13 | |
| SCHEMBL4137088 | 0.98 | MAPT (0.46) | MAPTCYP1A2RECQLKDM4EMMP13 | |
| SCHEMBL4063122 | 0.79 | SLC18A3 (0.50) | MAPTKDM4EMCL1SLC18A3 | |
| SCHEMBL15874614 | 0.79 | SLC18A3 (0.50) | MAPTKDM4EMCL1SLC18A3 | |
| SCHEMBL28417815 | 0.79 | SLC18A3 (0.50) | MAPTKDM4EMCL1SLC18A3 | |
| SCHEMBL15660493 | 0.79 | SLC18A3 (0.50) | MAPTKDM4EMCL1SLC18A3 | |
| SCHEMBL30882060 | 0.79 | SLC18A3 (0.50) | MAPTKDM4EMCL1SLC18A3 | |
| SCHEMBL19993836 | 0.78 | DDB1 (0.43) | CYP1A2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL190786 | 0.77 | SLC18A3 (0.51) | MAPTKDM4EMCL1SLC18A3 | |
| SCHEMBL15874652 | 0.77 | SLC18A3 (0.51) | MAPTKDM4EMCL1SLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436005-B2 | Macrocyclic pyrimidine derivatives | ABBOTT LABORATORIES (US) | 2013-05-07 | — | — | US | disclosed |
| US-20090253678-A1 | MACROCYCLIC PYRIMIDINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253678-A1 | MACROCYCLIC PYRIMIDINE DERIVATIVES | DPYD, TYMS, TYMP | MAPT 2013/4885CYP1A2 1655/4885RECQL 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.